IGHV Mutational Status Testing in Chronic Lymphocytic Leukemia

Overview

Journal Am J Hematol

Specialty Hematology

Date 2017 Jun 8

PMID 28589701

Citations 24

Authors

Jennifer Crombie

Matthew S Davids

Affiliations

Soon will be listed here.

Abstract

As the therapeutic landscape for chronic lymphocytic leukemia (CLL) continues to expand, biological predictors of response to therapy are becoming increasingly important. One such predictive biomarker is the mutational status of the variable region of the immunoglobulin heavy chain (IGHV) gene, which is a powerful predictor of duration of response and overall survival with chemoimmunotherapy (CIT). As this test may influence choice of therapy between CIT and novel agents, it is critical that providers understand how mutational status is determined and the limitations of testing. Here, we describe the details of IGHV mutational status testing, highlighting the appropriate way to interpret this information and best apply it to the care of patients with CLL.

Citing Articles

BCL-2 dependence is a favorable predictive marker of response to therapy for chronic lymphocytic leukemia.

Chong S, Lu J, Valentin R, Lehmberg T, Eu J, Wang J Mol Cancer. 2025; 24(1):62.

PMID: 40025512 PMC: 11874845. DOI: 10.1186/s12943-025-02260-7.

The Analysis of Plasma Proteomics for Luminal A Breast Cancer.

Zhao M, Jiang Y, Kong X, Liu Y, Gao P, Li M Cancer Med. 2024; 13(23):e70470.

PMID: 39641443 PMC: 11622152. DOI: 10.1002/cam4.70470.

Melanoma as Subsequent Primary Malignancy in Hematologic Cancer Survivors-A Literature Review.

Halmagyi S, Ungureanu L, Trufin I, Apostu A, Senila S J Clin Med. 2024; 13(15).

PMID: 39124768 PMC: 11313577. DOI: 10.3390/jcm13154501.

Multiple omics levels of chronic lymphocytic leukemia.

Turk A, ceh E, Calin G, Kunej T Cell Death Discov. 2024; 10(1):293.

PMID: 38906881 PMC: 11192936. DOI: 10.1038/s41420-024-02068-2.

MicroRNAs: Potential prognostic and theranostic biomarkers in chronic lymphocytic leukemia.

Ali A, Mahla S, Reza V, Hossein A, Bahareh K, Mohammad H EJHaem. 2024; 5(1):191-205.

PMID: 38406506 PMC: 10887358. DOI: 10.1002/jha2.849.

References

Gladstone D, Swinnen L, Kasamon Y, Blackford A, Gocke C, Griffin C . Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. Leuk Lymphoma. 2011; 52(10):1873-81. PMC: 3790144. DOI: 10.3109/10428194.2011.585529. View

Roberts A, Davids M, Pagel J, Kahl B, Puvvada S, Gerecitano J . Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med. 2015; 374(4):311-22. PMC: 7107002. DOI: 10.1056/NEJMoa1513257. View

Ghia P, Stamatopoulos K, Belessi C, Moreno C, Stilgenbauer S, Stevenson F . ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. Leukemia. 2006; 21(1):1-3. DOI: 10.1038/sj.leu.2404457. View

Gentile M, Shanafelt T, Rossi D, Laurenti L, Mauro F, Molica S . Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood. 2016; 128(16):2093-2095. PMC: 5524531. DOI: 10.1182/blood-2016-07-728261. View

Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A . Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012; 72(20):5307-16. PMC: 3763938. DOI: 10.1158/0008-5472.CAN-12-1615. View

Gladstone D, Blackford A, Cho E, Swinnen L, Kasamon Y, Gocke C . The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2012; 12(2):132-7. PMC: 3612932. DOI: 10.1016/j.clml.2011.12.005. View

Fischer K, Bahlo J, Fink A, Goede V, Herling C, Cramer P . Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2015; 127(2):208-15. DOI: 10.1182/blood-2015-06-651125. View

Landau D, Tausch E, Taylor-Weiner A, Stewart C, Reiter J, Bahlo J . Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526(7574):525-30. PMC: 4815041. DOI: 10.1038/nature15395. View

Heyman B, Volkheimer A, Weinberg J . Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL. Blood Cancer J. 2016; 6(7):e440. PMC: 5030375. DOI: 10.1038/bcj.2016.49. View

10.

Calis J, Rosenberg B . Characterizing immune repertoires by high throughput sequencing: strategies and applications. Trends Immunol. 2014; 35(12):581-590. PMC: 4390416. DOI: 10.1016/j.it.2014.09.004. View

11.

Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H . Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111(12):5446-56. PMC: 2972576. DOI: 10.1182/blood-2007-06-093906. View

12.

Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P . Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am J Hematol. 2017; 92(4):375-380. DOI: 10.1002/ajh.24660. View

13.

Molica S, Shanafelt T, Giannarelli D, Gentile M, Mirabelli R, Cutrona G . The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. Am J Hematol. 2016; 91(11):1090-1095. PMC: 5072993. DOI: 10.1002/ajh.24493. View

14.

Trbusek M, Malcikova J, Smardova J, Kuhrova V, Mentzlova D, Francova H . Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukemia. 2006; 20(6):1159-61. DOI: 10.1038/sj.leu.2404195. View

15.

Guo A, Lu P, Galanina N, Nabhan C, Smith S, Coleman M . Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget. 2015; 7(4):4598-610. PMC: 4826229. DOI: 10.18632/oncotarget.6727. View

16.

Byrd J, Furman R, Coutre S, Burger J, Blum K, Coleman M . Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015; 125(16):2497-506. PMC: 4400288. DOI: 10.1182/blood-2014-10-606038. View

17.

Damle R, Wasil T, Fais F, Ghiotto F, Valetto A, Allen S . Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999; 94(6):1840-7. View

18.

Wiestner A, Rosenwald A, Barry T, Wright G, Davis R, Henrickson S . ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003; 101(12):4944-51. DOI: 10.1182/blood-2002-10-3306. View

19.

Hamblin T, Davis Z, Gardiner A, Oscier D, Stevenson F . Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999; 94(6):1848-54. View

20.

Thompson P, Tam C, OBrien S, Wierda W, Stingo F, Plunkett W . Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2015; 127(3):303-9. PMC: 4760129. DOI: 10.1182/blood-2015-09-667675. View